Drug Trial Radar · NCT05117138
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
39
Planned (sponsor's estimate)
Start
Jan 1, 2022
Primary completion
Dec 1, 2023
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer of the head and neck (HNSCC),AMT-253 CAR-T cells in patients with moderate or far advanced melanoma.
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
Interventions
AMT-116 CAR-T cellsBiological
1. Classical "3+3" dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled. 2. Classical "3+3" dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled.
AMT-253 CAR-T cellsBiological
1.The classic "3 + 3" dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip. 2.3 \~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10\^8 cells. 3.3 \~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10\^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: 24 weeks
- Overall Response Rate (ORR)Time frame: 24 weeks
- One year recurrence rateTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.